Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000019706 | SCV002572430 | likely pathogenic | Amyotrophic lateral sclerosis type 9 | 2022-08-30 | criteria provided, single submitter | clinical testing | Variant summary: ANG c.155G>A (p.Ser52Asn) results in a conservative amino acid change located in the Ribonuclease A-domain (IPR023412) adjacent to the nuclear localization sequence (NLS) of the encoded protein. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251492 control chromosomes. c.155G>A has been reported in the literature in at-least one individual affected with Amyotrophic Lateral Sclerosis Type 9 who continues to be cited by others (example, Wu_2007, Narain_2019). At least one publication reports experimental evidence evaluating an impact on protein function (Wu_2007). The most pronounced variant effect results in loss of both ribonucleotytic activity and nuclear translocation activity. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
OMIM | RCV000019706 | SCV000040004 | pathogenic | Amyotrophic lateral sclerosis type 9 | 2007-12-01 | no assertion criteria provided | literature only |